Co-Sponsored by the: U.S. Food & Drug Administration (FDA) and the National Brain Tumor Society (NBTS)
In collaboration with: Accelerate Brain Cancer Cure (ABC2); American Brain Tumor Association (ABTA); Friends of Cancer Research (FOCR); Kidney Cancer Research Alliance (KCCure); LUNGevity Foundation; Melanoma Research Alliance (MRA); Metastatic Breast Cancer Alliance (MBC Alliance); RANO (Response Assessment in Neuro-Oncology) and Society for NeuroOncology (SNO)
There is a paucity of effective treatments for patients with central nervous system (CNS) metastases. Moreover, there are few clinical trials and a need for more attention to this high unmet medical need. One impediment to product development for CNS metastases is uncertainty on the optimal clinical trial endpoints and study designs for evaluating products. This unique workshop will bring key stakeholders together to evaluate what is needed to advance development of effective products and consider optimal endpoints and clinical trial designs related to this topic.
Location: FDA White Oak Campus
Building 31, Room 1503 – Great Room
10903 New Hampshire Avenue
Silver Spring, MD 20993
Persons interested in attending this public workshop must register online by 5 PM on March 20, 2019.
If you need special accommodations due to a disability, please contact Joan Todd before 5:00 PM, EST, March 7, 2019.
[maxbutton id=”41″ url=”https://www.eventbrite.com/e/product-development-for-central-nervous-system-cns-metastases-public-workshop-tickets-53818045222″ text=”Click HERE to Learn More & Register” ]
